皓元医药(688131) - 2023 Q1 - 季度财报

Financial Performance - The company's total revenue for Q1 2023 reached RMB 418.37 million, representing a year-on-year increase of 39.46%[6] - The net profit attributable to shareholders decreased by 25.83% to RMB 46.24 million, while the net profit after deducting non-recurring gains and losses fell by 28.64% to RMB 41.96 million[6] - Total operating costs for Q1 2023 were ¥354,607,032.39, up 61.1% from ¥219,865,620.60 in Q1 2022[25] - Net profit for Q1 2023 was ¥46,068,348.53, a decrease of 25.5% from ¥61,771,891.90 in Q1 2022[26] - Operating profit for Q1 2023 was ¥47,936,796.00, down 29.3% from ¥67,898,249.96 in Q1 2022[25] - Basic earnings per share for Q1 2023 were ¥0.43, compared to ¥0.60 in Q1 2022[26] Research and Development - Research and development expenses totaled RMB 50.52 million, an increase of 50.95% year-on-year, accounting for 12.08% of total revenue[6] - Research and development expenses for Q1 2023 were ¥50,524,023.51, an increase of 50.9% from ¥33,470,762.57 in Q1 2022[25] - The company is actively enhancing its R&D capabilities with centers in multiple cities and is expanding its business operations internationally[12] - The company continues to focus on innovation and has implemented stock incentive plans for over 300 employees to support its strategic goals[13] - The company is focusing on technological innovation and industrial upgrades as part of its strategic initiatives[16] Assets and Liabilities - The company's total assets increased by 5.53% to RMB 3.80 billion compared to the end of the previous year[8] - The total current assets as of March 31, 2023, amounted to CNY 1,897,890,597.80, an increase from CNY 1,822,869,836.48 at the end of 2022, reflecting a growth of approximately 4.0%[19] - The total non-current assets as of March 31, 2023, were CNY 123,084,820.60, slightly up from CNY 75,590,454.31 at the end of 2022[19] - Total liabilities amounted to ¥1,408,819,244.19, up 11.3% from ¥1,265,778,968.40 in Q1 2022[21] Cash Flow - The company reported a significant increase in cash outflows from operating activities, primarily due to increased inventory purchases and higher employee compensation costs[11] - The net cash flow from operating activities was CNY -147,839,554.95, compared to CNY -3,784,513.39 in the same period last year[28] - The total cash outflow from operating activities was CNY 521,737,913.70, compared to CNY 262,392,414.67 in Q1 2022[28] - The total cash inflow from operating activities was CNY 373,898,358.75, an increase from CNY 258,607,901.28 in the same quarter last year[28] - The cash inflow from investment activities was CNY 341,445,562.65, significantly higher than CNY 47,474,574.57 in Q1 2022[29] - The cash inflow from financing activities was CNY 193,321,701.42, up from CNY 112,400,000.00 in Q1 2022[29] Shareholder Information - The top shareholder, Shanghai Anxu Information Technology Co., Ltd., holds 32.47% of the company's shares, totaling 34,736,166 shares[15] - The company reported a total of 7,674,660 shares held by the top shareholder, representing a significant portion of the total shares outstanding[16] - The company has a total of 1,989,724 shares held by China Industrial Bank, indicating strong institutional support[17] Workforce - The company expanded its workforce to 3,581 employees, an increase of 213 employees compared to the end of the previous year, primarily in production and technical roles[13] Other Information - The company has not reported any significant mergers or acquisitions during the quarter[18] - There are no significant changes in the company's financing or margin trading activities reported for this period[18] - Cash and cash equivalents decreased to CNY 304,569,982.51 from CNY 460,137,636.91, representing a decline of about 33.7%[19] - Inventory increased significantly to CNY 1,070,725,002.15, up from CNY 910,876,848.98, indicating a rise of approximately 17.6%[19] - Accounts receivable rose to CNY 407,502,261.10 from CNY 336,860,225.55, marking an increase of around 20.9%[19] - The ending balance of cash and cash equivalents was CNY 300,142,110.84, down from CNY 853,568,279.69 at the end of Q1 2022[29]